You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 11, November 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE 39TH ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, WASHINGTON, DC, MAY 12 TO MAY 14, 1986-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tumoricidal Effects and Patient Survival After Hyperthermic Liver Perfusion

Joseph L. Skibba, MD, PhD; Edward J. Quebbeman, MD, PhD

Arch Surg. 1986;121(11):1266-1271.


Abstract

• Hyperthermic liver perfusion for four hours at 42.0°C to 42.5°C was used as the sole modality of therapy for cancer confined to the liver in eight patients. Two patients had melanoma, one had cholangiolar carcinoma of the liver, and five had liver metastases from colorectal carcinoma. Two postoperative deaths occurred, both in patients with colorectal carcinoma metastases. Response was indicated by computed tomographic and/or liver biopsy or autopsy findings of tumor necrosis. There were five responders to hyperthermic liver perfusion among the six survivors. Hyperthermic liver perfusion was an effective tumoricidal agent for hepatic metastases from colorectal cancer; ie, tumor necrosis occurred in all five patients, as well as in the two who died, as shown by autopsy findings. Conversion to a disease-free state with hyperthermic perfusion may be possible with other treatment modalities used in combination or sequence.

(Arch Surg 1986;121:1266-1271)



Author Affiliations

From the Medical College of Wisconsin and the Clement J. Zablocki Veterans Administration Medical Center, Milwaukee.


Footnotes

Accepted for publication Aug 14, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 11, 1986.

Reprint requests to Department of Surgery, Medical College of Wisconsin, 8700 W Wisconsin Ave, Milwaukee, WI 53226 (Dr Skibba).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Percutaneous Isolated Hepatic Perfusion for Chemotherapy: A Phase 1 Study
Savier et al.
Arch Surg 2003;138:325-332.
ABSTRACT | FULL TEXT  

Current Status of Isolated Hepatic Perfusion With or Without Tumor Necrosis Factor for the Treatment of Unresectable Cancers Confined to Liver
Alexander et al.
The Oncologist 2000;5:416-424.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.